Rein Therapeutics Inc. (RNTX)
NASDAQ: RNTX · Real-Time Price · USD
0.81985
+0.0258 (3.26%)
Aug 11, 2026, 2:58 PM EDT - Market open
Rein Therapeutics Employees
Rein Therapeutics had 10 employees as of December 31, 2025. The number of employees decreased by 1 or -9.09% compared to the previous year.
Employees
10
Change (1Y)
-1
Growth (1Y)
-9.09%
Revenue / Employee
n/a
Profits / Employee
-$5,020,800
Market Cap
70.13M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 10 | -1 | -9.09% |
| Dec 31, 2024 | 11 | -4 | -26.67% |
| Dec 31, 2023 | 15 | 9 | 150.00% |
| Dec 31, 2022 | 6 | -3 | -33.33% |
| Dec 31, 2021 | 9 | 1 | 12.50% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Champions Oncology | 214 |
| Alps Group | 93 |
| XBiotech | 87 |
| PMV Pharmaceuticals | 54 |
| Cardiff Oncology | 31 |
| Spero Therapeutics | 25 |
| iBio, Inc. | 20 |
| LeonaBio | 19 |
RNTX News
- 7 days ago - Rein Therapeutics Announces Publication of Landmark LTI-03 Clinical Data in Nature Communications - GlobeNewsWire
- 21 days ago - Rein Therapeutics announces RENEW clinical trial open for enrollment - TheFly
- 21 days ago - Rein Therapeutics Announces Phase 2 RENEW Trial Now Enrolling Across All Five Countries - GlobeNewsWire
- 22 days ago - Rein Therapeutics Transcript: AGM 2026 - Transcripts
- 22 days ago - Maxim starts Rein Therapeutics at Buy amid de-risked LTI-03 program - TheFly
- 22 days ago - Rein Therapeutics initiated with a Buy at Maxim - TheFly
- 2 months ago - Rein Therapeutics Expands Phase 2 RENEW Trial into United Kingdom - GlobeNewsWire
- 2 months ago - Rein Therapeutics Proxy statement: Proxy filing - Filings